Results 91 to 100 of about 22,830 (226)

Correlation of ROS1 (D4D6) Immunohistochemistry with ROS1 Fluorescence In Situ Hybridization Assay in a Contemporary Cohort of Pulmonary Adenocarcinomas

, 2022
Sambit K. Mohanty Objective Repressor of Silencing (ROS1) gene rearrangement in the lung adenocarcinomas is one of the targetable mutually exclusive genomic alteration.
Shivmurti Kumar, Shivani Sharma, Sourav K. Mishra, Shilpy Jha, Mohit Bhardwaj, Ekta Jain, Sambit K. Mohanty, Matthew Geller, Aditi Dewan, Gauri Munjal, Mallika Dixit, Deepika Jain   +11 more
core   +1 more source

Importance of Testing for ROS1 Rearrangements in Non-Small Cell Lung Cancer in the Era of Targeted Therapy in a Latin American Country

Cancer Management and Research
Alvaro Osorio,1,2 Liliana Fernandez-Trujillo,2,3 Juan G Restrepo,1,2 Luz F Sua,2,4 Catalina Proaño,5 Valeria Zuñiga-Restrepo2 1Department of Internal Medicine, Oncology Service, Fundación Valle Del Lili, Cali, Colombia; 2Faculty of Health Sciences ...
Osorio A, Fernandez-Trujillo L, Restrepo JG, Sua LF, Proaño C, Zuñiga-Restrepo V   +5 more
doaj  

VCL::ROS1 : A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing

Clinical Pathology
Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with ROS1 gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners documented in the existing literature.
Anurag Mehta, Himanshi Diwan, Shrinidhi Nathany, Ullas Batra, Manoj Gupta, Manoj Kumar Panigrahi, Dushyant Kumar, Sakshi Mattoo, Aayushi Singh   +8 more
openaire   +2 more sources

Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2‐Negative Breast Cancer: A Real‐World Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and ...
Franciele Hinterholz Knebel, Maurício Fernando Silva Almeida Ribeiro, Rudinei Diogo Marques Linck, Isabela Flauzino Ferreira, Cibele Masotti, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata Carvalho Oliveira, Daniele Coelho Duarte, Paula Fontes Asprino, Ernande Xavier dos Santos, Elisângela Monteiro Coser, Dimitrios Kleftogiannis, Louise J. Barber, Marco Gerlinger, João Victor Machado Alessi, Andrea Kazumi Shimada, Fernando Costa Santini, Ciro Eduardo de Souza, Olavo Feher, Gilberto de Castro Junior, Frederico Perego Costa, Max Senna Mano, Artur Katz, Anamaria Aranha Camargo, Fabiana Bettoni   +26 more
wiley   +1 more source

Oncogenic activity of the EZR-ROS1 fusion gene.

, 2013
(A) Schematic representation of EZR, ROS1, EZR-ROS1, and deletions/mutations of EZR-ROS1 genes. The domain organization is shown. C-C: coiled-coil domain; TM: transmembrane; C-ERMAD: C-terminal ERM associated domain. (B) ROS1 phosphorylation in wild-type
Yasuhito Arai (281672), Tatsuhiro Shibata (281685), Akihiko Yoshida (281677), Koji Tsuta (281676), Hiroyuki Takahashi (281673), Yasushi Totoki (39825), Takashi Kohno (111032), Hitoshi Tsuda (281683), Michihiro Mutoh (281679), Hiromi Nakamura (281674), Hisao Asamura (281678), Natsuko Hama (281675), Fumie Hosoda (281681)   +12 more
core   +1 more source

Economic value and clinical role of minimally invasive, biopsy‐based diagnostics in non‐small cell lung cancer

Cancer Cytopathology, Volume 134, Issue 10, October 2026.
Abstract Background Precision oncology requires diagnostic sampling that delivers molecularly actionable material quickly and safely. In non‐small cell lung cancer (NSCLC), core‐needle biopsy (CNB) remains common. Yet fine‐needle aspiration (FNA) has re‐emerged with rapid on‐site evaluation (ROSE), optimized cell blocks, and next‐generation sequencing.
Jiayuan Guo, Bo Franzén, Rolf Lewensohn, Martin Hysek, Linus Jönsson   +4 more
wiley   +1 more source

Lonely Driver ROS1 [PDF]

Journal of Thoracic Oncology, 2017
Savic S, Rothschild S, Bubendorf L
openaire   +3 more sources

Envonalkib Versus Crizotinib in Treatment‐Naive ALK‐Positive Non‐Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study

MedComm, Volume 7, Issue 10, October 2026.
Envonalkib provides robust and durable benefit in treatment‐naïve ALK‐positive NSCLC, with median PFS of 30.4 months versus 12.0 months for crizotinib. Exploratory biomarker analyses showed that concurrent driver alterations and p53 pathway dysfunction reduce treatment efficacy.
Jie Huang, Yuanyuan Wang, Haishuang Sun, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen, Shouan Ren, Jianying Zhou, Wu Zhuang, Xintian Qin, Lejie Cao, Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu, Lin Zhang, Xinyuan Zhao, Wenfeng Fang, Jing Li, Li Zhang, Yunpeng Yang   +25 more
wiley   +1 more source

The result of direct sequencing in ROS1-rearranged NSCLC.

, 2015
(A) SDC4:ROS1 (E2/E32). (B) SDC4:ROS1 (E4/E32). (C) SDC4:ROS1 (E4/E34).
Ma-Yan Huang (41842), Jian-Yong Shao (41845), Jing Wang (4865), Fang Wang (105926), Sha Fu (445944), Yong-Bin Lin (729064), Zi-Chen Zhang (511377), Ying Liang (13730), Wen-Jian Cen (729065)   +8 more
core   +1 more source

Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China

Journal of Comparative Effectiveness Research
The treatment of non-small-cell lung cancer (NSCLC) has progressed from histology-oriented cytotoxic therapy to the era of molecular biology-oriented targeted therapy and immunotherapy.
Hua Zhong, Jun Lu, Mengzhao Wang, Baohui Han   +3 more
doaj   +1 more source